Cytokinetics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited consolidated financial statements. Cytokinetics is a late-stage biopharmaceutical company developing muscle-function therapies; it has no commercial product sales to date.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Total revenue | $0.8 million | $4.6 million |
| Operating expenses | $127.1 million | $129.1 million |
| Operating loss | $126.2 million | $124.5 million |
| Net loss | $135.6 million | $131.3 million |
| Net loss per share, basic and diluted | $1.33 | $1.38 |
| Net cash used in operating activities | $129.5 million | $122.3 million |
| Cash, cash equivalents and investments | $634.3 million at March 31, 2024 | $655.4 million at December 31, 2023 |
Revenue consisted of collaboration-related research and development reimbursements; there were no milestone revenues in Q1 2024. Gross margin is not applicable because the company has no commercial product sales.
Research and development expense was $81.6 million, up $2.1 million year over year. Cardiac-program expense increased $20.6 million to $66.8 million, mainly reflecting aficamten trials; skeletal-program expense fell $21.0 million to $0.7 million following discontinuation of COURAGE-ALS. General and administrative expense declined $4.2 million to $45.5 million, primarily due to lower commercial-readiness service costs.
Cash and investments declined $21.0 million from year-end. Investing activities provided $32.6 million, largely from investment maturities, while financing activities provided $103.8 million, including $93.6 million net proceeds from the ATM equity offering. The cash flow statement reports a $7.0 million increase in cash, cash equivalents and restricted cash during the quarter.
At March 31, 2024, reported borrowings were $606.6 million net: $56.8 million term loan, $20.8 million 2026 Notes and $529.0 million 2027 Notes. Separately, revenue-participation liabilities totaled $390.2 million. Working capital was $549.8 million; total liabilities were $1.204 billion and stockholders’ deficit was $396.2 million. Management believes existing cash, investments and investment income will fund projected requirements for at least 12 months after filing, while expecting ongoing losses and operating cash outflows.
Material changes and business developments
- Revenue fell $3.8 million year over year, reflecting the absence of the $2.5 million Ji Xing aficamten nHCM trial-initiation milestone recognized in Q1 2023 and lower partner reimbursements, including no further Astellas reimbursement after its maximum contribution was collected.
- Net loss increased $4.4 million. Higher operating loss and $3.9 million more non-cash interest on royalty-participation liabilities were partly offset by higher interest and other income.
- The company issued 1.24 million shares through its ATM program for $93.6 million net proceeds. Weighted-average shares increased to 101.9 million from 95.2 million in Q1 2023; 104.9 million shares were outstanding on May 8, 2024.
- The 2027 Notes have $540 million principal outstanding. Holders’ conversion condition was triggered based on an April 1, 2024 calculation, making the notes convertible at holders’ option in Q2 2024; the company said the condition was not met during Q1. The condition is reassessed quarterly.
Outlook, programs and key risks
- Aficamten: SEQUOIA-HCM, a Phase 3 trial in obstructive HCM, met its primary endpoint and all 10 prespecified secondary endpoints, according to the company. It reported a placebo-adjusted improvement in peak oxygen uptake of 1.74 mL/kg/min (p=0.000002); safety was described as comparable to placebo, with LVEF below 50% observed in 3.5% of aficamten patients versus 0.7% of placebo patients. MAPLE-HCM and ACACIA-HCM are ongoing Phase 3 trials. Management planned to submit an FDA NDA for oHCM in Q3 2024 and an EMA application in Q4 2024. These are forward-looking plans, not approvals.
- Omecamtiv mecarbil: FDA issued a Complete Response Letter in February 2023, concluding GALACTIC-HF alone did not establish substantial evidence of effectiveness and that an additional trial was required. FDA denied the company’s appeal in November 2023. After quarter-end, on May 7, 2024, the company disclosed that it voluntarily withdrew its EMA application following committee feedback that benefits could not be found to outweigh risks based on GALACTIC-HF alone. The company is assessing continued development. This limits the program’s near-term regulatory prospects and also means the associated $50 million and $25 million Royalty Pharma loan tranches were unavailable.
- Funding and dilution: Management expects continuing losses and significant research, development and potential commercial-readiness spending. The company may need additional collaboration, equity or debt financing; availability and terms are uncertain. The ATM facility permits up to $300 million in aggregate offerings, and further equity issuance could dilute shareholders.
- Debt and royalty obligations: The company has substantial convertible debt and royalty-participation obligations. Royalty Pharma tranche 4 provides up to $75 million following positive SEQUOIA-HCM results, subject to a minimum draw requirement of $50 million; a further $100 million tranche is conditional on FDA acceptance of an aficamten NDA by the specified deadline. Loan repayments include substantial financing costs.
- Other risks: Clinical-trial execution, patient enrollment, regulatory review, manufacturing and supply reliance on third parties, reimbursement and pricing, competition, intellectual-property protection, and the need to retain key personnel. The filing reports no legal proceedings and no material change in market-risk exposure. Management judged disclosure controls effective as of March 31, 2024.
The filing references 2024 revenue and net-cash-use guidance but the supplied text does not provide clear numerical guidance. It provides no separate margin guidance.
Important facts for investors to verify
- Current aficamten trial progress and whether the planned Q3 2024 FDA submission and Q4 2024 EMA submission occurred, were accepted, or require additional data.
- Cash burn, investment balances and financing needs relative to management’s stated minimum 12-month liquidity outlook.
- Potential conversion, cash settlement or dilution related to the 2027 Notes, and the terms and timing of any Royalty Pharma tranche draw.
- The impact of omecamtiv mecarbil’s FDA CRL and EMA application withdrawal on future development, collaboration proceeds and related royalty liabilities.
- ATM share issuance and dilution, as well as commercial-readiness spending and prospects for future collaboration or product revenue.